Adriana Marques

Adriana Marques, MD, is a clinical researcher within the National Institute of Allergy and Infectious Disease at the National Institutes of Health in the United States. Her research interests include Lyme disease, herpes zoster, herpes simplex and chronic Epstein-Barr virus disease.

Dr Marques is one of the investigators assigned to the NIH Post-Infectious ME/CFS Study.

Notable studies

 * 2017, Early Disseminated Lyme Disease Causing False Positive Serology for Primary Epstein-Barr Virus Infection - Report of 2 Cases."'Abstract - False positive serology for Lyme disease was reported in patients with acute infectious mononucleosis. Here we describe two patients with early-disseminated Lyme disease who were misdiagnosed with infectious mononucleosis based on false positive tests for primary Epstein-Barr virus infection.'"
 * 2015, Laboratory Diagnosis of Lyme Disease - Advances and Challenges (FULL TEXT)
 * 2011, Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States (FULL TEXT)"'Abstract - Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by markedly elevated levels of antibody to EBV or EBV DNA in the blood and EBV RNA or protein in lymphocytes in tissues. We present our experience with CAEBV during the last 28 years, including the first 8 cases treated with hematopoietic stem cell transplantation in the United States. Most cases of CAEBV have been reported from Japan. Unlike CAEBV in Japan, where EBV is nearly always found in T or natural killer (NK) cells in tissues, EBV was usually detected in B cells in tissues from our patients. Most patients presented with lymphadenopathy and splenomegaly; fever, hepatitis, and pancytopenia were common. Most patients died of infection or progressive lymphoproliferation. Unlike cases reported from Japan, our patients often showed a progressive loss of B cells and hypogammaglobulinemia. Although patients with CAEBV from Japan have normal or increased numbers of NK cells, many of our patients had reduced NK-cell numbers. Although immunosuppressive agents, rituximab, autologous cytotoxic T cells, or cytotoxic chemotherapy often resulted in short-term remissions, they were not curative. Hematopoietic stem cell transplantation was often curative for CAEBV, even in patients with active lymphoproliferative disease that was unresponsive to chemotherapy. These studies are registered at http://www.clinicaltrials.gov as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific T-cell studies, and NCT00578539 for the hematopoietic stem cell transplantation protocol."

Online presence

 * PubMed
 * Twitter
 * Facebook
 * Website
 * YouTube

Learn more

 * NIH - Adriana Marques